Question 1

What to stack with thymosin alpha-1?

Accepted Answer

We report what it has been studied beside, and we do not suggest a combination. The list is useful mainly for what is missing from it. Every tested partner is a prescription medicine, and a 2010 review sums up the hepatitis side by saying thymalfasin, in combination with the standard of care, may be helpful as an adjuvant. An adjuvant is something added to a main therapy to help it work, not a therapy in its own right. In cancer, a 2026 review says Tα1 could enhance the efficacy of conventional and emerging cancer therapies, including chemotherapy, radiotherapy, and immune checkpoint inhibitors. Note the word could. That review is describing a hope backed by mixed trials, which the sections below take apart one pairing at a time. What does not appear anywhere in the research behind this page is a trial of Ta1 next to another research peptide, such as BPC-157 or TB-500. Any such pairing is untested in the studies covered here, and the hepatitis and cancer results do not carry over to it.

Question 2

Is Ta1 the same as TB-500, and does one record vouch for the other?

Accepted Answer

No on both counts. The two come from the same cattle thymus extract and share little else, a point made in full on the Thymosin Alpha-1 overview. A 2007 review notes that thymosin fraction 5 consists of a mixture of polypeptides and improves immune response, and that is the extract both molecules were first pulled from. The same review then adds a twist: however, none of the isolated peptides were really thymic hormones. So the shared surname comes from a lab history rather than a shared job. On the beta side, the review is frank that very little is known about molecular mechanisms mediating the effects attributed to extracellular beta-thymosins. That is the comparison that matters for a reader. Ta1 has randomised human trials in hepatitis and cancer, while thymosin beta-4, the parent of TB-500, sits on a separate and much thinner record set out at the TB-500 overview. A result for one is not evidence for the other.

Question 3

How did it compare with interferon in hepatitis B?

Accepted Answer

Close, in a trial too small to separate them. One study found hepatitis B virus DNA clearance at six months in 9 of 17 patients receiving TA1, compared with 10 of 16 patients treated with interferon alfa-2b and 4 of 15 historical controls. Interferon is an injected immune signal that was a standard hepatitis B therapy at the time. Historical controls are past patients from records, not people enrolled side by side, which makes that third number the weakest of the three. A 2015 editorial, pooling English and Chinese trials, concludes that in CHB, Tα-1monotherapy is effective in suppressing viral replication compared with untreated control or conventional interferon. CHB is chronic hepatitis B, and monotherapy means Ta1 given alone. Read that as level with an old standard, measured against a benchmark that has since moved, rather than as better than what a patient would be offered now.

Question 4

What did adding it to interferon do in hepatitis C?

Accepted Answer

In the early trials, it roughly doubled the response, and on its own it did nothing measurable. Given alone, the number of patients who achieved normal serum alanine aminotransferase (ALT) levels did not differ significantly between TA1 and placebo. Paired with interferon, hepatitis C virus RNA clearance occurred in 65% of patients treated with combination therapy and 29% of patients treated with IFN-alpha 2b alone. A three-arm trial found normalization of ALT levels at six months in 37.1% of patients receiving combination therapy, 16.2% of patients receiving IFN-alpha 2b alone, and 2.7% of patients receiving placebo. ALT is a liver enzyme that falls as liver inflammation settles. The pattern is consistent: Ta1 added something to interferon and little by itself. Those trials together held 162 patients, which is the scale the later phase 3 work was meant to check.

Question 5

Did the hepatitis C combination hold up in larger trials?

Accepted Answer

Not on its main measure, and that matters more than the small early wins. A 2010 review records that in a large phase-III randomized study conducted in Europe, thymalfasin did not improve the rate of sustained virologic responses. A sustained response means the virus stays undetectable after therapy ends, which is the result patients and doctors care about. A registered study fits that description, listed as Thymosin Alpha-1 in Combination With Peg-Interferon Alfa- 2a and Ribavirin for the Therapy of Chronic Hepatitis C Nonresponsive to the Combination of IFN and Ribavirin, a PHASE3 trial marked COMPLETED. A smaller open-label triple therapy study in 40 Hispanic patients reports that 21.1% achieved an SVR at week 72. Open-label means everyone knew who got what, and with no comparison arm that figure cannot show what Ta1 added. Small early trials that look good, followed by a larger trial that does not, is a familiar pattern, and this is an example of it.

Question 6

Has it been paired with hepatitis B antiviral pills?

Accepted Answer

Yes, and these are the pairings closest to how hepatitis B is handled today. A 2015 editorial reports that most of the combination therapy of Tα-1 plus either lamivudine or IFN-α showed better effects on HBV DNA suppression and HBeAg seroconversion. Lamivudine is an antiviral pill, and HBeAg seroconversion is a blood marker that the virus is less active. A 2024 study compared entecavir, a newer antiviral pill, against thymalfasin + entecavir combination therapy, and found lower levels of HA, LN, and IVC in the observation group. Those three letters stand for blood markers of liver scarring. The same authors also write that entecavir is highly effective in the clinical treatment of HBeAG-positive chronic hepatitis B, so the question there was what Ta1 adds on top. A 2010 review adds that pilots studies in patients with chronic hepatitis B treated with thymalfasin in combination with interferon or nucleoside analogue, showed a 70% complete sustained response rate. Pilot studies without a control arm cannot say how much of that 70% belongs to Ta1.

Question 7

What happened when it was added to chemotherapy?

Accepted Answer

This is where the best-designed cancer comparison sits. A bowel cancer trial allocated patients by random number table to an experimental group (0-199, XELOX chemotherapy and thymalfasin for injection) and control group (200-400, XELOX chemotherapy). XELOX is a standard two-drug chemotherapy for bowel cancer, and here it was given after surgery. The group given Ta1 had fewer problems after surgery, both early and late, and fewer cancers came back in the same place or spread to other organs. That is a strong set of results from 400 patients, and two cautions apply. It was a single hospital, and the summary gives no sign that patients or doctors were blinded to who got what. Results like this need repeating elsewhere before they can be called settled, and the larger registered trial described on the Thymosin Alpha-1 dosage page is the kind of study that would do it.

Question 8

Has it been combined with cancer immunotherapy?

Accepted Answer

Yes, mostly in lung cancer, and the main study cannot answer the question a reader asks. A look back at the records of 120 lung cancer patients split them into three groups, and one group of 34 got immunotherapy and Ta1 with no chemotherapy. The immunotherapy in question is the class of cancer drugs that take the brakes off the immune system, and the other two groups got chemotherapy on top. Patients lived longer, and lived longer before the cancer grew, in the two groups that also got chemotherapy. Because every group got Ta1, that result is about chemotherapy, not about Ta1, and the study had no group without it. A 2023 paper puts the idea as a hope rather than a result, saying a boost to how well these drugs work has been hinted at. A registered rectal cancer study that pairs radiation, chemotherapy, one of these drugs and thymalfasin before surgery is marked COMPLETED. A completed registry entry is not a published result.

Question 9

What about the leukaemia combination?

Accepted Answer

It produced the most striking numbers on this page and the weakest design. In an observational study of a regimen of chidamide and decitabine plus thymalfasin simultaneously, all 24 patients had response to this epigenetic regimen accompanied with decreased measurable residual disease. Measurable residual disease is the small number of leukaemia cells still detectable after therapy. The patients had relapsed early after a stem cell transplant, which makes a full response notable. The study reports an overall survival rate of 79.2% (19/24). There was no comparison group, so the study cannot say what Ta1 contributed beyond the two other drugs. A three-drug result tells you about the regimen as a whole and not about any one part of it.

Question 10

Has thymosin alpha-1 been used as the yardstick for something else?

Accepted Answer

Once, and the design says something about its standing. A 2026 trial in bowel cancer patients after chemotherapy randomized participants (1:4:1) to receive placebo (N = 33), PEG (N = 132), or thymalfasin (N = 33). PEG there is a herbal decoction made from a medicinal fungus, and the trial's main measures were immune cell counts in the blood. The primary outcomes included changes in peripheral blood immune cell subsets (CD4+/CD8+ ratio and percentage of NK cells), which are the kind of numbers Ta1 is expected to move. In a trial built that way, thymalfasin is the established option that the new remedy is measured against. The published summary reports the decoction's results and gives no clear figure for the thymalfasin arm, so it does not tell you how the two compared.

Question 11

How does it compare with other thymic peptides?

Accepted Answer

It is one of a family, and the family has never been ranked within the research behind this page. A 1992 review describes how the thymus produces several putative thymic hormones: thymosin alpha 1, thymulin and thymopoietin. Putative means supposed, which fits the later view that none of them turned out to be true hormones. A 1989 survey lists thymosin alpha 1 with thymopentin, splenopentin and thymulin among a dozen agents meant to boost the immune system. A 1994 review groups it with two old drugs, levamisole and isoprinosine, as things that may nudge the immune system toward one kind of T-cell response. Being listed together is not the same as being compared. None of these reviews measured one against another, and of the group only thymalfasin went on to the approval record described on the Thymosin Alpha-1 overview.

Question 12

Are there modified versions of thymosin alpha-1?

Accepted Answer

Proposed ones, and one built into a virus in the lab. A 2023 patent survey says chemical changes could help the peptide last longer in the body, get into cells more easily and hold its shape. Lasting longer here means standing up to the enzymes that chop proteins into pieces. A 2022 purity analysis suggests cutting, swapping or changing the last building block in the chain, because that is the part that breaks down. The most unusual version is a cancer-killing virus built to make the peptide itself, and in that work the peptide, whether added or made by the virus, helped the virus attack tumours by way of killer T cells. That was work in the lab and in mice. None of these altered forms has a human result in the studies covered here, so they say nothing yet about how they compare with the original.

Question 13

What would a fair comparison need?

Accepted Answer

Three things the current record mostly lacks. The first is a modern comparator. The hepatitis B comparisons ran against untreated patients, past records or interferon from the 1990s, and the field has moved on since. The second is blinding and scale, and the one large blinded study of Ta1 in pancreatitis found it did not reduce the incidence of IPN during the index admission. IPN is infection of dead pancreas tissue. That trial is not a comparison with another medicine, but it shows what tends to happen when a promising signal meets a properly blinded test. The third is a hard outcome, and the 2001 review put it plainly: its effects on morbidity and mortality remain to be seen. Morbidity and mortality mean illness and death. Virus counts and immune cell ratios are measured against those in the end, and most of the comparisons on this page stop short of them.

Thymosin Alpha-1 comparisons and stacks